Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of bendamustine when given with
or without cyclophosphamide in preventing graft versus host disease (GVHD) in patients
undergoing stem cell transplant. Drugs used in chemotherapy, such as bendamustine and
cyclophosphamide, work in different ways to stop the growth of cancer cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving
chemotherapy and total body irradiation before or after a stem cell transplant helps kills
cancer cells that are in the body and helps make room in the patient's bone marrow for new
blood-forming cells (stem cells) to grow. Sometimes, the transplanted cells from a donor can
attack the body's normal cells called GVHD. Giving tacrolimus, mycophenolate mofetil, and
filgrastim after the transplant may stop this from happening.